Table 1 Baseline patients characteristics (Group A = with BPF; Group B = without BPF; acute PPE = post-pneumonectomy empyema within 90 days after pneumonectomy; BPF = bronchopleural fistula; NSCLC = non-small cell lung cancer; PM = pleural mesothelioma; PE = pneumonectomy).
From: Accelerated treatment concept in postpneumonectomy empyema with bronchopleural fistula
Characteristics | Cohort n = 58 | Group A n = 19 | Group B n = 39 | p value |
|---|---|---|---|---|
Male gender | 44 (75.9%) | 16 (84.2%) | 28 (71.8%) | 0.154 |
Age at surgery | 62.7 ± 11.5 | 64.5 ± 7.7 | 61.8 ± 12.9 | 0.21 |
Cardio-vascular comorbidities | 33 (56.9%) | 11 (57.9%) | 22 (56.4%) | 0.458 |
Pulmonal comorbidities | 19 (32.8%) | 8 (42.1%) | 11 (28.2%) | 0.149 |
Right sided | 33 (56.9%) | 16 (84.2%) | 17 (43.6%) | < 0.001 |
Acute PPE | 38 (65.5%) | 11 (57.9%) | 27 (69.2%) | 0.201 |
BPF | 19 (32.8%) | - | - | |
NSCLC | 24 (41.4%) | 10 (52.6%) | 14 (35.9%) | 0.116 |
Squamous | 13 (22.4%) | 9 (47.4%) | 4 (10.3%) | |
Adeno | 9 (15.5%) | 1 (5.3%) | 8 (20.5%) | |
Adeno-squamous | 1 (1.7%) | 0 (0%) | 1 (2.6%) | |
Poorly differentiated | 1 (1.7%) | 0 (0%) | 1 (2.6%) | |
PM | 22 (37.9%) | 8 (42.1%) | 14 (35.9%) | 0.327 |
Other malignancies | 6 (10.3%) | 0 (0%) | 6 (15.4%) | 0.037 |
Benign aetiology | 6 (10.3%) | 1 (5.3%) | 5 (12.8%) | 0.192 |
Neoadjuvant chemotherapy | 35 (60.3%) | 10 (52.6%) | 25 (64.1%) | 0.205 |
Adjuvant chemotherapy | 6 (10.3%) | 6 (31.6%) | 0 (0%) | 0.479 |
Adjuvant radiotherapy | 17 (29.3%) | 5 (26.3%) | 12 (30.8%) | 0.366 |
Extrapleural or extended PE | 43 (74.1%) | 11 (57.9%) | 32 (82.1%) | 0.025 |
